Sangamo Therapeutics (SGMOQ) Asset Writedowns and Impairment (2015 - 2025)
Sangamo Therapeutics (SGMOQ) posted quarterly Asset Writedowns and Impairment of $13.2 million for Q4 2025, up 1029.27% quarter-over-quarter from $1.2 million in Q2 2024.
Sangamo Therapeutics (SGMOQ) Asset Writedowns and Impairment (2015 - 2025) Analysis & Trends
Sangamo Therapeutics' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $13.2 million for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $13.2 million; the TTM figure through Dec 2025 stood at $13.2 million (up 139.72% YoY), while the FY2025 annual figure was $13.2 million, up 139.72% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $13.2 million, up from $1.2 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $44.8 million in Q3 2023, with the low at $200000.0 in Q4 2023.
- The 3-year median for Asset Writedowns and Impairment is $4.3 million (2023), against an average of $11.3 million.
- Peak annual rise in Asset Writedowns and Impairment reached 3.55% in 2024, while the deepest fall reached 3.55% in 2024.
- Sangamo Therapeutics' Asset Writedowns and Impairment stood at $200000.0 in 2023, then surged by 486.0% to $1.2 million in 2024, then surged by 1029.27% to $13.2 million in 2025.
- Business Quant data shows SGMOQ's Asset Writedowns and Impairment at $13.2 million in Q4 2025, $1.2 million in Q2 2024, and $4.3 million in Q1 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.24 Mn |
| Dec 31, 2025 | 13.24 Mn |
| Jun 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 1.17 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Dec 31, 2023 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 44.80 Mn |
| Sep 30, 2023 | 44.80 Mn |
| Mar 31, 2023 | 4.20 Mn |
| Mar 31, 2023 | 4.20 Mn |
| Mar 31, 2015 | 1.87 Mn |
| Mar 31, 2015 | 1.87 Mn |